Screening for atrial fibrillation with the WatchBP device as compared to current clinical practice: a cost-analysis.
|
|
- Kristina Moody
- 5 years ago
- Views:
Transcription
1 Screening for atrial fibrillation with the WatchBP device as compared to current clinical practice: a cost-analysis. Introduction Atrial Fibrillation Atrial fibrillation (AF) is the most common cardiac arrhythmia. It affects over one percent of the general UK population and is related to one fifth of all strokes (European Heart Rhythm et al. 2010). For this reason it causes a major burden on healthcare: 0.62% of national healthcare expenditure in 1995 and increased to 0.97% in It is expected that the number of AF patients will increase by 40% in the coming two decades due to the ageing population and western lifestyle (Stewart, 2004). Many patients with AF have no symptoms (33%) and are not aware of its presence and therefore remain undiagnosed. If these patients suffering with AF could be diagnosed and treated at an early stage, the risk of stroke can be reduced by 68% (European Heart Rhythm et al., 2010). Current clinical practice According to the current Nice guidelines (NICE_CG36, 2011) AF should be screened opportunistically. This means that pulse palpation should be performed among patients presenting breathlessness/dyspnoea, palpitations, syncope/dizziness, chest discomfort or had a stroke/tia. Although many patients can be diagnosed with AF the method is not very accurate and requires an extra effort and extra costs ( 1.83 (Hobbs et al., 2005)). In addition, its accuracy can differ largely between studies (sensitivity ranging from % and specificity ranging from 69-81%) and observers (Morgan and Mant, 2002, Hobbs et al., 2005, Sudlow et al., 1998). The WatchBP device The WatchBP Home is an automated blood pressure monitor with an implemented AF detection system. When a GP or Patient measures blood pressure using the WatchBP, the device automatically screens for AF without any extra effort. As a simple explanation, the algorithm of the device calculates the irregularity index (SD divided by mean) based on interval times between heartbeats and if the irregularity index is above a certain threshold value a patient is diagnosed as having AF. If a patient performs self-measurements at home and the WatchBP Home detects AF, it gives a warning that a visit to the GP is required. The systems accuracy has been investigated in several scientific studies and showed high diagnostic accuracy (Stergiou et al. 2009; Wiesel et al. 2009). Although, the WatchBP device has never been directly compared to pulse palpation for AF screening, results from different clinical studies consistently show a higher diagnostic accuracy for the WatchBP (Stergiou et al. 2009; Wiesel et al. 2009) device than for pulse palpation as compared to the gold standard: a 12-lead ECG assessed by a consultant (Hobbs et al., 2005, Morgan and Mant, 2002, Somerville et al., 2000, Sudlow et al., 1998). Based on the results of the SAFE study the AF detector of the WatchBP monitor shows an even higher rate of accuracy for the detection of AF than a GP or nurse using a 12-lead ECG system (Hobbs et al. 2005) as compared to a 12- lead ECG assessment by a consultant. Patients without symptoms Pulse palpation is recommended for patients experiencing symptoms as described earlier. However, many people have no symptoms at all. Their numbers are estimated from one third (European Heart Rhythm et al., 2010) to the majority of AF patients (NICE_CG36, 2011). According to current guidelines these patients probably will remain undiagnosed, with a high risk of getting stroke in the future. With the WatchBP Home device patients can be screened for AF during blood pressure measurements without any extra effort. Since blood pressure is commonly measured on a routine basis during visits to the GP, asymptomatic patients who otherwise would not be screened for AF can be diagnosed with the WatchBP device. It is therefore estimated that with the WatchBP device more patients will be detected at an early stage so that treatment can be initiated earlier leading to an overall reduction in strokes. 1
2 ECG s If a doctor feels pulse irregularities an ECG should be performed for confirmation (NICE_CG36). Results from the SAFE study showed that this led to diagnosing a new AF patient in 17.5% (one of every 5.7 subjects) of all ECG screenings or 82.5% unnecessarily performed ECG s ( 16 (Hobbs et al., 2005)). Therefore, replacing pulse palpation by the WatchBP device might reduce the amount of unnecessary ECG s. The present cost-analysis report estimated the costs for AF screening and treatment when using the WatchBP device and compared this against pulse palpation; the current standard for AF screening. 2
3 Methods Strategies for Cost analyses For the cost calculation we compared AF screening by mean of pulse palpation against the WatchBP device. For the cost analysis the NICE costing report for the management of atrial fibrillation (NICE, 2006) was used as a platform, the costs for screening, treatment and adverse events were adopted and adjusted for inflation to 2011 figures. The first strategy follows the assumption that all new AF patients will be screened for AF, (patients with and without symptoms). Sensitivity analyse For cost analyses we varied the parameters for patients who would be considered for screening or not (patients with and without AF-related symptoms) and used different costs for stroke per patient per year. Symptoms Additional cost analyses were performed with the assumption that a part of all AF positive patients have no symptoms. It is estimated that 35% (European Heart Rhythm et al., 2010, NICE_CG36, 2011) to 50% (NICE_CG36, 2011) of all patients with AF have no symptoms. In accordance to the current recommended guidelines, these patients are not considered for pulse palpation. Under the assumption that these patients undergo routine blood pressure measurement during their visit at the GP s practice these patients undergo AF screening at the same time when blood pressure is measured with the WatchBP device. Accuracy of the screening methods For the reliability of pulse palpation we verified 4 studies (Morgan and Mant, 2002, Somerville et al., 2000, Sudlow et al., 1998, Hobbs et al., 2005). We excluded two studies because pulse palpation was not compared to a 12-lead ECG (Sudlow et al., 1998) or the study was carried out at only one GP s practice and therefore may not be representative for overall healthcare (Somerville et al., 2000). As a consequence the calculations were performed with the results obtained from the studies of Morgan (91% sensitivity, 74% specificity) and Hobbs (87.2% sensitivity, 81.3% specificity). For the accuracy of the WatchBP device with AF detection system we used the results of studies from Wiesel (97% sensitivity and 89% specificity) and Stergiou (100% sensitivity and 89% specificity) (Wiesel et al., 2009, Stergiou et al., 2009). For cost calculation the average cost based on the results of the studies of Hobbs and Morgan were compared to the average costs based on the results of the studies of Wiesel and Stergiou AF incidence of the GP population For the estimation of the UK incidence we followed the example from the NICE costing report of 2006 (NICE, 2006) and used the annual incidence of 0.175% which equalizes 87,000 new cases per year. Based on the sensitivity and specificity results of the SAFE-trial for pulse palpation and the additional finding that in 1 out of every 5.7 patients with irregular pulse, AF presence is confirmed by 12-lead ECG, we calculated that this number would be found with an AF incidence of 4.4% using the following formula: (incidence x sensitivity) / ((incidence x sensitivity + (1-incidence)) x (1-specificity)). This incidence is higher than the general AF incidence but we estimate that this is representative for the population that is screened for AF (high risk, symptoms) as these are commonly elder people with certain risk factors. Costs assumptions For the cost analysis the NICE costing report for the management of atrial fibrillation (NICE, 2006) was used as a platform, which means that the costs for screening and treatment were adopted and adjusted for inflation to 2011 figures. The inflation was estimated at 5% per year. This was similar to the NICE costing report using a HCSC inflation rate of 27% to adjust prices from 2001 to 2006 (NICE_CG36, 2011). 3
4 Table A, costs for treatment from the NICE costing report 2006 and adjusted for inflation to 2011 Costs ECG Palpitations Anti-Coagulants Stroke Major Bleeds Minor Bleeds Costs for stroke In the NICE costing report the annual average cost for stroke was estimated at 7,800, which was used for the current de novo cost-analysis with adjustment for 2011 ( 9,906). However, as more studies estimated the costs for stroke an extra analysis was performed using the estimated costs of 44k per patient as the annual costs for stroke (Saka et al., 2009) ( In addition, it was calculated at what costs for stroke the costs for screening would be offset due to number of stroke (costs) prevented. Proportions of patients treated and adverse events Further, we adopted the proportion assumptions from the NICE costing report. We followed the proposal that 56% of detected AF patients should use anticoagulants (A-C), 32% of all patients use aspirin. The percentage of stroke annually prevented by Warfarin was estimated at 4.3% and for aspirin this was estimated 0.9%. The percentage of adverse events was estimated at 2.4% for major bleeds and 15.8% for minor bleeds for those patients using anti-coagulation. Costs for pulse palpation The cost of pulse palpation were estimated at 1.83 as obtained from the SAFE-trial (Hobbs et al., 2005). For the detection with the WatchBP device we calculated no costs as it was assumed that blood pressure measurement is performed among these patients when visiting a GP. 4
5 Results Cost effectiveness analysis I The first example of the cost effectiveness analysis assumes that all new AF incidences will be screened for AF This analysis is rather similar to the NICE costing report with the exception that the number of false positives has been taken into account. Based on the accuracy of pulse palpation (Morgan, Hobbs) it is estimated that from the 87,000 new AF cases each year 7,830 (Morgan) or 11,180 (Hobbs) are not detected (False Negatives). See table I in the appendix. Based on the finding that a stroke cost 9,906 per patient per year, both screening methods cost money. Due to the higher sensitivity of the WatchBP device more AF patients will be diagnosed than with pulse palpation (85,695 vs. 77,495 patients) leading to higher costs for treatment ( 23.3M vs. 21.1M) and adverse events related to anti-coagulation drugs ( 3.2M vs. 3.1M) but more cost savings due to a higher number of stroke prevention ( 22.9M vs. 20.7M). The higher specificity of the WatchBP device leads to a lower number of patients falsely diagnosed as AF positive (207,930 vs. 422,381) and therefore a reduction in the number of ECGs (293,625 vs. 499,877) and related costs for ECG assessment( 10.5M vs. 18.0M). The overall cost for screening with pulse palpation is further increased by the costs for palpation ( 4.6M) where screening with the WatchBP does not require extra costs. See Table 1a. Overall the WatchBP device will save approx. 11.6M as compared to pulse palpation based on the average pulse palpation costs (Morgan and Hobbs) minus the average WatchBP costs (Wiesel, Stergiou). In addition, it is estimated that screening with the WatchBP device will prevent 221 (11%) more strokes than by pulse palpation. See Table 1b Table1a, costs for screening and treatment, when all patients would be considered for atrial fibrillation screening Costs AC Major Bleeds Minor Bleeds Palpitations ECG's Strokes prevented Total costs Wiesel (WatchBP) Stergiou (WatchBP) Morgan (PP) Hobbs (PP) AC, indicates anti-coagulants; pp, pulse palpation Table 1b, Strokes prevented and overall costs for atrial fibrillation screening and treatment Strokes prevented Studies (n) Wiesel (WatchBP) 2275 Stergiou (WatchBP) 2346 Morgan (PP) 2134 Hobbs (PP) 2044 PP indicates pulse palpation See also Table I in the appendix for more detailed information. 5
6 Cost effectiveness analysis II Extra The second example is based on the assumption that a part of all AF positive patients have no symptoms. Patients without symptoms are likely to be detected by the WatchBP device during routine blood pressure measurement, whereas they would remain undiagnosed by pulse palpation because there would be no indication for screening. IIa If from all new AF positive patients 35% have no symptoms then (87,000*65%) 56,550 patients would be considered for pulse palpitation. With the WatchBP device all patients would be screened for AF under the assumption that their blood pressure is routinely measured during a visit at the GP. Despite the fact that with the WatchBP more patients will be diagnosed with WatchBP than with pulse palpation and thus treatment costs, costs for adverse events, screening costs and ECG assessment costs are increased, the overall AF screening and treatment costs are approx. 2.6M lower (Table 2a.a) due to cost savings related to a higher number of strokes (952) prevented (Table 2a.b). Table2a.a, costs for screening and treatment when 35% of all new atrial fibrillation patients are without symptoms Costs AC Major Bleeds Minor Bleeds Palpitations ECG's Strokes prevented Total costs Wiesel (WatchBP) Stergiou (WatchBP) Morgan (PP) Hobbs (PP) Table 2a.b, strokes prevented when 35% of all new atrial fibrillation patients are without symptoms Strokes prevented Studies (n) Wiesel (WatchBP) 2275 Stergiou (WatchBP) 2346 Morgan (PP) 1387 Hobbs (PP) 1329 PP indicates pulse palpation IIB If from all new AF positive patients 50% would be without any symptoms then screening with the WatchBP device would lead to 1.2M higher costs on average (Table 2b.a) and 1266 more strokes being prevented on average (Table 2b.b) as compared to pulse palpation. The lower costs for pulse palpation are mainly due to the fact that less ECG s are performed and fewer patients are treated with Warfarin. See Table IIb in the appendix for the detailed overview. Table2b.a, costs for screening and treatment when 50% of all new atrial fibrillation patients are without symptoms Costs AC Major Bleeds Minor Bleeds Palpitations ECG's Strokes prevented Total costs Wiesel (WatchBP) Stergiou (WatchBP) Morgan (PP) Hobbs (PP)
7 Table 2b.b, strokes prevented when 50% of all new atrial fibrillation patients are without symptoms Strokes prevented Studies (n) Wiesel (WatchBP) 2275 Stergiou (WatchBP) 2346 Morgan (PP) 1067 Hobbs (PP) 1022 See also Tables IIA and B in the appendix for more detailed information. 7
8 Cost effectiveness analysis III III Costs for stroke The above cost analyses took into account 9,906 as the annual costs for stroke. However, it is indicated that the annual costs for stroke may be higher. For this reason we performed the same analysis again when using 44,000 per patient as the annual costs for stroke (Saka et al., 2009) ( Since changing in costs has no consequences for the number of strokes prevented only the costs are provided in below examples IIIa If 87,000 new AF patients are considered for screening with the WatchBP device and pulse palpation, both screening methods show the average cost savings for healthcare of 64.6M and 45.4M on average for WatchBP and pulse palpation, respectively (See Table 3a). Table3a, costs for screening and treatment, when all patients would be considered for atrial fibrillation screening and cost for stroke is 44,000 per patient per annum Anticoagulants Major Bleeds Minor Bleeds Palpitations ECG's Strokes prevented Total Costs costs Wiesel (WatchBP) Stergiou (WatchBP) Morgan (PP) Hobbs (PP) IIIb If 35% of all new AF patients are without symptoms this would mean that the number of strokes that are prevented by screening with pulse palpation will reduce to 1358 together with related cost savings for healthcare to 29.4M on average, whereas for WatchBP both stroke prevention and related cost-savings remain similar as (See Table IIIb in the Appendix). Table3b, costs for screening and treatment when 35% of all new atrial fibrillation patients are without symptoms and cost for stroke is 44,000 per patient per annum Anticoagulants Major Bleeds Minor Bleeds Palpitations ECG's Strokes prevented Total Costs costs Wiesel (WatchBP) Stergiou (WatchBP) Morgan (PP) Hobbs (PP) IIIc When 50% of all new AF patients are without symptoms the number of strokes prevented and related costssavings for pulse palpation will diminish further as compared to WatchBP, leading to 1045 strokes prevented and 22.7M cost-saving for pulse palpation. The number of strokes prevented and related cost-saving for WatchBP remain unchained (See Table IIIc in the Appendix). Table3c, costs for screening and treatment when 35% of all new atrial fibrillation patients are without symptoms and cost for stroke is 44,000 per patient per annum Anticoagulants Major Bleeds Minor Bleeds Palpitations ECG's Strokes prevented Total Costs costs Wiesel (WatchBP) Stergiou (WatchBP) Morgan (PP) Hobbs (PP) See also Tables IIIA, B and C in the appendix for more detailed information. 8
9 Break-even point Since there are some uncertainties about the annual cost for stroke we decided to calculate at which point screening for AF would be cost effective using the fact that the cost savings for stroke prevention offsets the cost of screening. The so called break-even costs for stroke were 16,090, 15,990 for Wiesel and Stergiou (WatchBP) and and for Morgan and Hobbs (PP), respectively (Figure 1). This was calculated with the assumption that all new AF cases (87.000) were considered for pulse palpation. When assuming that some new AF patients are without symptoms and thus are not considered for pulse palpation, the break-even cost for stroke would be lower for pulse palpation but not for WatchBP. 9
10 Total costs screening and treatment 50,000,000 40,000,000 30,000,000 20,000,000 10,000, ,000,000-20,000,000-30,000,000-40,000,000 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20,000 22,000 24,000 26,000 28,000 Wiesel (WatchBP) 32,054,92 27,504,61 22,954,30 18,403,99 13,853,68 9,303,380 4,753, ,762-4,347,54-8,897,85-13,448,1-17,998,4-22,548,7-27,099,0 Stergiou (WatchBP) 32,960,55 28,123,57 23,432,53 18,741,49 14,050,45 9,359,412 4,668,372-22,668-4,713,70-9,404,74-14,095,7-18,786,8-23,477,8-28,168,9 Morgan (PP) 45,346,87 41,078,03 36,809,18 32,540,34 28,271,49 24,002,64 19,733,80 15,464,95 11,196,10 6,927,262 2,658,415-1,610,43-5,879,27-10,148,1 Hobbs (PP) 39,393,37 35,305,13 31,216,89 27,128,65 23,040,40 18,952,16 14,863,92 10,775,68 6,687,443 2,599,202-1,489,04-5,577,28-9,665,52-13,753,7 Figure 1, relationship between total costs for screening and treatment of atrial fibrillation (y-ax) and costs for stroke per patient per annum (x-ax) 10
11 Discussion As compared to pulse palpation screening for AF with the WatchBP device will lead to approx. 45% cost-savings ( 12M) and 11% reduction in the number of strokes (221 strokes). As screening with the WatchBP leads to a lower number of false negatives more patients will be treated for AF, which leads to higher costs for anticoagulant drugs and related adverse events (major and minor bleeds). On the other hand, screening with the WatchBP device leads to a lower number of false positives so that less 12-lead ECG s for confirmation are required. When screening for AF with the WatchBP device it is estimated that for the detection of one new AF case 3.4 ECG s are required. This means a reduction with more than 2 unnecessary ECG s per newly diagnosed AF patient as compared to pulse palpation based on the results of the SAFE-trial (Hobbs et al., 2005). In the above findings it has been taken into account that all new AF cases are screened for AF by both methods. However, approx 35 to 50% of all AF patients do not experience any symptoms related to the disease. In practice this would mean that these patients would not be considered for pulse palpation. It is estimated that this would lead to a higher difference between screening methods in the number of newly diagnosed AF patients since symptomless AF patients can be detected with the WatchBP device when blood pressure measurement is routinely performed at the GP s visit. This would lead to a higher difference between both methods in the number of strokes prevented and also leads to higher costs for treatment. What would be the consequences for overall healthcare costs depends on what would be the exact costs for stroke per patient per annum is. 12-lead ECG When finding an AF positive patient with the WatchBP device it is then recommended that a 12-lead ECG is assessed for confirmation. However, it should be realized that, according to the results of the SAFE trial a 12- lead ECG assessed by a GP does not seem to show higher accuracy for diagnosing AF than the WatchBP device as compared to 12-lead ECG assessment by a consultant (Hobbs et al., 2005, Wiesel et al., 2009, Stergiou et al., 2009). The chance of a false negative result is higher for the ECG assessed by a GP or nurse than for the WatchBP device. Therefore, instead of performing a 12-lead ECG in the physicians office one could also consider performing extra measurements in the GP s practice with the WatchBP device or give the WatchBP Home A to a patient to take multiple measurements at home. As screening with the WatchBP is cheaper in both measurement and device, this would decrease costs for AF screening even further. For this it must be taken into account that the ECG also can diagnose other arrhytmia s or cardiac diseases, which cannot be done with the WatchBP device. Therefore the ECG device cannot be totally replaced by the WatchBP devicein the GP s practice. Finally, it should be mentioned that clinical studies to the WatchBP device showed that among the patients, who were diagnosed as false positive, a part of them had other arrhythmia s and therefore the confirming ECG s may not all be classified as unnecessary. Paroxysmal Atrial fibrillation Outside the use in the GP s practice the WatchBP Home A device can also be given to patients suspected of having paroxysmal AF to take measurements at home. In practice this means that the device can be given instead of a 24-h ambulatory device. When the WatchBP Home A would be used by patients who have paroxysmal AF without symptoms this may reduce costs for overall healthcare as the WatchBP Home A device is cheaper than the average ambulatory ECG device. Patients with hypertension are at increased risk of having (paroxysmal) AF. Due to their hypertension these patients may have purchased a blood pressure device themselves for performing self-measurement of blood pressure at home. If these patients would purchase the WatchBP Home A which is at a similar price range as most validated home blood pressure monitors are, they may detect the presence of paroxysmal AF which is mostly asymptomatic (Lip et al., 2008). Since patients with paroxysmal AF have a similar stroke risk as patients with permanent AF (Friberg et al., 2010) this could also help to prevent the occurrence of stroke in the future. 11
12 The cost savings for paroxysmal AF have not been taken into account for the present cost analysis, because the incidence and prevalence is difficult to estimate. In addition, it cannot be estimated how many patients would purchase the WatchBP Home A device for performing self-measurement of blood pressure at home. If the WatchBP devices are implemented in general clinical practice it may help to improve the insight into the incidence and prevalence of paroxysmal AF in the UK. In addition, when the WatchBP home A is used for patients at home for regular blood pressure monitoring it could also lead to better blood pressure control as patients are more aware of their blood pressure, which can lead to improved lifestyle and better adherence to treatment. In addition, the implemented schedule for self-measurement of blood pressure at home helps patients to obtain a reliable estimate of a patient s true blood pressure value. In fact it may give a more reliable estimate of a patients blood pressure value that could reduce unnecessary treatment of hypertension and improve blood pressure control (Verberk et al., 2005, Verberk et al., 2007) At the present cost-analysis the price of the monitor has not been taken into account as it is assumed that GP s need to have a blood pressure monitor anyway. However, when considered that the WatchBP Home A device costs approximately 75 per device and is used for an average period of three years, the annual costs will be 25 per device per year. Assuming that the total screening will be covered by GP the costs of the devices will be 1M extra per year. If GP s would prefer to use a professional blood pressure monitor with AF detector, a device that is more sophisticated with extra possibilities and will cost approx 500. Assuming that this device will be used 5 years on average, the annual costs are estimated at 100 which will be 4M extra costs for the device per year. Current NICE guidelines state that everyone with an irregular pulse should be given an ECG the average cost of performing this function is approx 30 of which only 1 in 5 are found to have AF. The WatchBP device would cut down the need for an ECG by some 40% thus reducing hospital waiting times and overall healthcare costs. Conclusion The WatchBP device can help improving AF screening in regular clinical practice, without any extra efforts. It is less liable to observer bias than pulse palpation. When the WatchBP device is used for routine blood pressure measurement in the GP s practice, it will also diagnose AF positive patients without AF-related symptoms, a group that remain undetected when screened by pulse palpation. It is expected to lead to a lower number of unnecessary ECG s for confirmation of AF presence. The higher number of patients detected with AF by the WatchBP device as compared to pulse palpation would lead to higher costs for treatment and related adverse events, which are (partly) offset by the cost savings due to increased stroke prevention. The WatchBP Home A device can help detect paroxysmal atrial fibrillation. As the WatchBP Home A device is not more expensive than other validated blood pressure monitors, paroxysmal AF might also be widely detected by consumers who measure their blood pressure at home and would otherwise not visit their GP. 12
13 References EUROPEAN HEART RHYTHM, A., EUROPEAN ASSOCIATION FOR CARDIO-THORACIC, S., CAMM, A. J., KIRCHHOF, P., LIP, G. Y., SCHOTTEN, U., SAVELIEVA, I., ERNST, S., VAN GELDER, I. C., AL-ATTAR, N., HINDRICKS, G., PRENDERGAST, B., HEIDBUCHEL, H., ALFIERI, O., ANGELINI, A., ATAR, D., COLONNA, P., DE CATERINA, R., DE SUTTER, J., GOETTE, A., GORENEK, B., HELDAL, M., HOHLOSER, S. H., KOLH, P., LE HEUZEY, J. Y., PONIKOWSKI, P., RUTTEN, F. H., GUIDELINES, E. S. C. C. F. P., VAHANIAN, A., AURICCHIO, A., BAX, J., CECONI, C., DEAN, V., FILIPPATOS, G., FUNCK-BRENTANO, C., HOBBS, R., KEARNEY, P., MCDONAGH, T., POPESCU, B. A., REINER, Z., SECHTEM, U., SIRNES, P. A., TENDERA, M., VARDAS, P. E., WIDIMSKY, P., DOCUMENT, R., AGLADZE, V., ALIOT, E., BALABANSKI, T., BLOMSTROM-LUNDQVIST, C., CAPUCCI, A., CRIJNS, H., DAHLOF, B., FOLLIGUET, T., GLIKSON, M., GOETHALS, M., GULBA, D. C., HO, S. Y., KLAUTZ, R. J., KOSE, S., MCMURRAY, J., PERRONE FILARDI, P., RAATIKAINEN, P., SALVADOR, M. J., SCHALIJ, M. J., SHPEKTOR, A., SOUSA, J., STEPINSKA, J., UUETOA, H., ZAMORANO, J. L. & ZUPAN, I. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace, 12, FRIBERG, L., HAMMAR, N. & ROSENQVIST, M. (2010) Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J, 31, HOBBS, F. D., FITZMAURICE, D. A., MANT, J., MURRAY, E., JOWETT, S., BRYAN, S., RAFTERY, J., DAVIES, M. & LIP, G. (2005) A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess, 9, iii-iv, ix-x, LIP, G. Y., FRISON, L. & GRIND, M. (2008) Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med, 264, MORGAN, S. & MANT, D. (2002) Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract, 52, 373-4, NICE (2006) CG36 Atrial fibrillation: Cost impact report. NICE_CG36 (2011) Atrial Fibrillation. National clinical guideline for management in primary and secondary care SAKA, O., MCGUIRE, A. & WOLFE, C. (2009) Cost of stroke in the United Kingdom. Age Ageing, 38, SOMERVILLE, S., SOMERVILLE, J., CROFT, P. & LEWIS, M. (2000) Atrial fibrillation: a comparison of methods to identify cases in general practice. Br J Gen Pract, 50, STERGIOU, G. S., KARPETTAS, N., PROTOGEROU, A., NASOTHIMIOU, E. G. & KYRIAKIDIS, M. (2009) Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Hum Hypertens, 23, STEWART, S. (2004) Epidemiology and economic impact of atrial fibrillation. J Cardiovasc Nurs, 19, SUDLOW, M., RODGERS, H., KENNY, R. A. & THOMSON, R. (1998) Identification of patients with atrial fibrillation in general practice: a study of screening methods. Bmj, 317,
14 VERBERK, W. J., KROON, A. A., KESSELS, A. G. & DE LEEUW, P. W. (2005) Home blood pressure measurement a systematic review. J Am Coll Cardiol, 46, VERBERK, W. J., KROON, A. A., LENDERS, J. W., KESSELS, A. G., VAN MONTFRANS, G. A., SMIT, A. J., VAN DER KUY, P. H., NELEMANS, P. J., RENNENBERG, R. J., GROBBEE, D. E., BELTMAN, F. W., JOORE, M. A., BRUNENBERG, D. E., DIRKSEN, C., THIEN, T. & DE LEEUW, P. W. (2007) Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension, 50, WIESEL, J., FITZIG, L., HERSCHMAN, Y. & MESSINEO, F. C. (2009) Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens, 22,
No. 1 cause of invalidity No. 2 cause of dementia No. 3 cause of death
STROKE statistics No. 1 cause of invalidity No. 2 cause of dementia No. 3 cause of death Every 6 seconds a person in the world has a STROKE regardless of age and gender. Worldwide 15 million people suffer
More informationSwitching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
British Journal of Clinical Pharmacology DOI:10.1111/bcp.12559 Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects Kenneth Todd Moore, 1 William Byra, 2 Seema
More informationDiagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation
(2009), 1 5 & 2009 Macmillan Publishers Limited All rights reserved 0950-9240/09 $32.00 www.nature.com/jhh ORIGINAL ARTICLE Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation
More informationBMJ Open. Secondary Subject Heading: Cardiovascular medicine, Diagnostics, General practice / Family practice
Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single lead ECG and modified BP monitors Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article Type:
More informationAntiarrhythmic drug therapy for the prevention of atrial fibrillation recurrences
2012 Update of the ESC Guidelines on the Management of Atrial Fibrillation Antiarrhythmic drug therapy for the prevention of atrial fibrillation recurrences Stefan H. Hohnloser J.W. Goethe University Frankfurt
More informationReview of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network
Review of devices for early AF detection Nadya Hamedi Primary Care cardiovascular pharmacist Health innovation Network n.hamedi@nhs.net HRC 2016 The ICC Birmingham UK 9-12 October 2016 PAN London AF Improvement
More informationRESEARCH INTRODUCTION
1 Department of Primary Care and General Practice, University of Birmingham, Birmingham B15 2TT 2 Health Economics Facility, Health Services Management Centre, University of Birmingham, Birmingham B15
More informationEuropean Heart Rhythm Association launches a practical guide on new oral anticoagulants in atrial fibrillation
European Heart Journal (2013) 34, 791 795 doi:10.1093/eurheartj/eht051 European Heart Rhythm Association launches a practical guide on new oral anticoagulants in atrial fibrillation The European Heart
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationStroke Prevention & Atrial Fibrillation. Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015
Stroke Prevention & Atrial Fibrillation Susanne Christie Arrhythmia Nurse Specialist 24 th September 2015 Learning Outcomes What is Atrial Fibrillation? Why is Atrial Fibrillation important? What causes
More informationThe case against structured screening for Atrial Fibrillation in General Practice
The case against structured screening for Atrial Fibrillation in General Practice THE CASE AGAINST STRUCTURED SCREENING FOR ATRIAL FIBRILLATION IN GENERAL PRACTICE or the PCCJ conference Nov 2015 r Ivan
More informationMedical technologies guidance Published: 16 January 2013 nice.org.uk/guidance/mtg13
WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension Medical technologies guidance Published: 16 January 2013 nice.org.uk/guidance/mtg13 NICE
More informationAF Stroke Prevention Through Screening, Intervention and Patient Choice
AF Stroke Prevention Through Screening, Intervention and Patient Choice Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GP Partner Westcliffe Medical Group Trustee AF Association Trustee
More informationOptimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationAtrial Fibrillation. Why It s Important. Updated on 2007 / 11 / 23. Microlife Corp ww.microlife.com. Page 1
Atrial Fibrillation Why It s Important Microlife Corp ww.microlife.com Updated on 2007 / 11 / 23 Page 1 CONTENT ORIGINAL PRESENTATION P3 ~ P13 UPDATED ASH ABSTRACT SUBMISSION INFORMATION INTERESTING LINK
More informationOptimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire
Optimising detection and stroke prevention strategies in patients with Atrial Fibrillation in West Hampshire Dr Chris Arden GP, Chandlers Ford GPSI Cardiology, Southampton West Hampshire CCG Cardiovascular
More informationDetection of Atrial Fibrillation Using a Modified Microlife Blood Pressure Monitor
nature publishing group Detection of Atrial Fibrillation Using a Modified Microlife Blood Pressure Monitor Joseph Wiesel 1, Lorenzo Fitzig 1, Yehuda Herschman 2 and Frank C. Messineo 1 Background Hypertension
More informationAtrial Fibrillation & Acute Stroke
Atrial Fibrillation & Acute Stroke Acute Stroke Stroke Facts Aetiology Thrombosis Classification outcomes Time is Brain Acute Stroke Over 5 million people die as a result of stroke and another 5 million
More informationIntroduction. CLINICAL RESEARCH Atrial fibrillation
European Heart Journal (2014) 35, 1856 1863 doi:10.1093/eurheartj/ehu048 CLINICAL RESEARCH Atrial fibrillation Efficacy and safety of apixaban compared with aspirin in patients who previously tried but
More informationASYMPTOMATIC ATRIAL FIBRILLATION: THE CASE FOR OPPORTUNISTIC SCREENING BY AUTOMATIC BLOOD PRESSURE MEASUREMENT IN THE COMMUNITY For peer review only
BMJ Open ASYMPTOMATIC ATRIAL FIBRILLATION: THE CASE FOR OPPORTUNISTIC SCREENING BY AUTOMATIC BLOOD PRESSURE MEASUREMENT IN THE COMMUNITY Journal: BMJ Open Manuscript ID bmjopen-0-00 Article Type: Research
More informationAsymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco
Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine
More informationDevice Equivalence Evaluation Form
Comparison of the Microlife BP A150 AFIB with the Microlife BP A100 Plus and Microlife BP A100 Device Equivalence Evaluation Form Devices Microlife BP A150 AFIB 9 Microlife BP A100 Plus 9 Microlife BP
More informationUpdates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
More informationAtrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency
Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation
More informationElectrocardiogram interpretation and arrhythmia management:
Research Gordon Begg, Kathryn Willan, Keith Tyndall, Chris Pepper and Muzahir Tayebjee Electrocardiogram interpretation and arrhythmia management: a primary and secondary care survey Abstract Background
More informationAtrial fibrillation. Understanding NICE guidance
Understanding NICE guidance Information for people who use NHS services Atrial fibrillation NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationYieldofscreeningforatrialfibrillationin primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination
Europace Advance Access published February 16, 2016 Europace doi:10.1093/europace/euv426 CLINICAL RESEARCH Yieldofscreeningforatrialfibrillationin primary care with a hand-held, single-lead electrocardiogram
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationAtrial fibrillation detection and management. Professor Lis Neubeck Head of Theme Long Term Conditions
Atrial fibrillation detection and management Professor Lis Neubeck Head of Theme Long Term Conditions Atrial fibrillation Most common cardiac arrhythmia Symptoms range from severely debilitating to none
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationAtrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study
Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study Staffan Björck, MD, PhD; Bo Palaszewski, PhD; Leif Friberg, MD, PhD; Lennart Bergfeldt, MD, PhD Background and
More informationAn update on managing patients with atrial fibrillation
Cardiovascular system haematology An update on managing patients with atrial fibrillation Most patients with atrial fibrillation can be managed in primary care. Patients should be referred for an initial
More informationAHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke. Version: 13 March 2017
AHSN Business Case User Guide: Improving AF Identification and Optimising Management to Prevent AF-Related Stroke Version: 13 March 2017 Introduction This business case template has been created so that
More informationErratum DAP39 ERRATUM. This Diagnostics Assessment Report was commissioned by the NIHR HTA Programme as project number 16/30/05
25 The clinical and cost effectiveness of lead-i electrocardiogram (ECG) devices for detecting atrial fibrillation using single-time point testing in primary care [DAP39] DAP39 ERRATUM Erratum This Diagnostics
More informationInfluence of decision-aids on oral anticoagulant prescribing among physicians: a
Article as originally submitted. Baicus C, Delcea C, Dima A, Oprisan E, Jurcut C, Dan GA. Influence of decision-aids on oral anticoagulant prescribing among physicians: a randomized trial. Eur J Clin Invest.
More informationUniversity of Groningen. Risk factors for atrial fibrillation incidence and progression Vermond, Robert Aldo
University of Groningen Risk factors for atrial fibrillation incidence and progression Vermond, Robert Aldo IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationTackling atrial fibrillation the health economics evidence
Tackling atrial fibrillation the health economics evidence Professor Gary Ford,CBE Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals
More informationOriginal Article CHA2DS2-VASc can better predict short-term prognosis in acute ischemic stroke patients with non-valvular atrial fibrillation
Int J Clin Exp Med 2016;9(3):6758-6764 www.ijcem.com /ISSN:1940-5901/IJCEM0019911 Original Article CHA2DS2-VASc can better predict short-term prognosis in acute ischemic stroke patients with non-valvular
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Clinical guideline for the management of atrial fibrillation
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Clinical guideline for the management of atrial fibrillation 1.1 Short title Atrial fibrillation 2 Background a) The National Institute
More informationDiagnosing atrial fibrillation using implantable devices
Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC
More informationEconomic Impact Evaluation Case Study: AliveCor Kardia Mobile
NHS Innovation Accelerator Economic Impact Evaluation Case Study: AliveCor Kardia Mobile 1. BACKGROUND The AliveCor Kardia Mobile ECG (Kardia Mobile) is a portable single-channel cardiac event recorder
More informationNew Routes to Integrated Care: Smart-phones and and changing GP roles
New Routes to Integrated Care: Smart-phones and and changing GP roles Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner
More informationAtrial fibrillation (AF) is the most common clinical arrhythmia,
Stroke Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population Implications for Stroke Prevention Johan Engdahl, MD, PhD; Lisbeth Andersson, RN; Maria Mirskaya, RN; Mårten Rosenqvist, MD,
More informationstroke.org.uk Atrial Fibrillation Reducing your risk of stroke
stroke.org.uk Atrial Fibrillation Reducing your risk of stroke What is AF? Atrial Fibrillation (AF) is the most common type of irregular heartbeat. Over 1 million people in the UK are living with the condition,
More informationPerformance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting
Europace (2017) 19, 29 39 doi:10.1093/europace/euw025 CLINICAL RESEARCH Atrial fibrillation Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric
More informationReal-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017
Real-World Insights from GARFIELD-AF Registry Presented at ESC Congress 2017 One of the aims of GARFIELD-AF is to assist physicians in their understanding of the risk of stroke in patients with atrial
More informationBIOTRONIK Clinical Studies IMPACT Clinical Study Patient Information. IMPACT Clinical Study: Patient Information Guide
BIOTRONIK Clinical Studies IMPACT Clinical Study Patient Information IMPACT Clinical Study: Patient Information Guide Introduction and Objectives IMPACT is a clinical research study. Approximately 2,700
More informationESC 2012: EHRA achievements EHRA Scientific Documents 2011/2012
WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER ESC 2012: EHRA achievements EHRA Scientific Documents 2011/2012 Prof. Dr. med. Paulus Kirchhof Chair in Cardiovascular Medicine University of Birmingham Centre
More informationEffectiveness of systematic screening for the detection of atrial fibrillation.
Royal College of Surgeons in Ireland e-publications@rcsi General Practice Articles Department of General Practice 1-1-2013 Effectiveness of systematic screening for the detection of atrial fibrillation.
More informationInpatient cardiac rehabilitation programs exercise therapy for patients undergoing cardiac surgery: National Korean Questionnaire Survey
Original Article Journal of Exercise Rehabilitation 2017;13(1):76-83 Inpatient cardiac rehabilitation programs exercise therapy for patients undergoing cardiac surgery: National Korean Questionnaire Survey
More informationFibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia
Gianluca Botto, FESC Elettrofisiologia Ospedale Sant Anna, Como Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia 20 min Presenter Disclosure Information n n n Research
More informationAtrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study
Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited A Population-Based Study Staffan Björck, MD, PhD; Bo Palaszewski, PhD; Leif Friberg, MD, PhD; Lennart Bergfeldt, MD, PhD Downloaded from
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationAF detection: What s new? Christopher B. Granger
AF detection: What s new? Christopher B. Granger Disclosures Research contracts: Apple, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Novartis, GSK, Medtronic Foundation, Pfizer,
More informationTOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J.
TOP 3: EMBRACE N Engl J Med Volume 370(26):2467-2477 June 26, 2014 David J. Gladstone et al Lucy Vieira MD FRCP Neurologist MUHC Receiving research funds AstraZeneca 2014-2016 Original Article Atrial Fibrillation
More informationG Medical Innovations Whitepaper
Arrhythmia monitoring in the palm of the hand: mobile 1-lead ECG The rising prevalence of cardiovascular disease (CVD), the leading cause of death in the USA and Europe, 1,2 has been the impetus for major
More informationonline publish-ahead-of-print 3 March 2016
European Heart Journal (2016) 37, 3203 3210 doi:10.1093/eurheartj/ehw077 CLINICAL RESEARCH Prevention and epidemiology Comparison of the ATRIA, CHADS 2,and CHA 2 DS 2 -VAScstrokeriskscoresinpredicting
More informationManagement of Atrial Fibrillation in Primary Care
Cardiac and Stroke Networks in Lancashire & Cumbria Lancaster Morecambe Carnforth and Garstang PBC North Lancashire Teaching PCT Management of Atrial Fibrillation in Primary Care Jeannie Hayhurst, CSNLC
More informationSafe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation
Europace (2017) 19, 1449 1453 doi:10.1093/europace/euw286 CLINICAL RESEARCH Atrial fibrillation Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation Emma Svennberg 1
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationIntroduction. Methods and results
Europace (2015) 1, 468 42 doi:10.1093/europace/euv025 EP WIRE How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationSingle time point case finding for Atrial Fibrillation: A review of methods of delivery and devices
Single time point case finding for Atrial Fibrillation: A review of methods of delivery and devices May 2017 Contents Foreword Page 3 List of abbreviations Page 4 1. Introduction Page 5 1.1 Incidence and
More informationSurgical Ablation of Atrial Fibrillation. Gregory D. Rushing, MD. Assistant Professor, Division of Cardiac Surgery
Surgical Ablation of Atrial Fibrillation Gregory D. Rushing, MD Assistant Professor, Division of Cardiac Surgery Midwestern Conference on Optimizing Electrophysiology Patient Care and Procedural Success
More informationDevice therapy in heartfailure Update of the ESC guidelines. Karl Swedberg
Device therapy in heartfailure Update of the ESC guidelines Karl Swedberg Professor of Medicine Department of emergency and cardiovascular medicine Sahlgrenska Academy University of Gothenburg, Sweden
More informationAtrial fibrillation (AF) is a common
Hellenic J Cardiol 2012; 53: 407-411 Editorial Comments on the 2012 Update of the ESC Guidelines for the Management of Atrial Fibrillation: What Is New and What Is Important for the Clinician? George Andrikopoulos
More informationWhat are the risk factors for AF?
Susan Mayor was paid in her capacity as a medical writer for her time to research and write this article for Boehringer Ingelheim. This article has been reviewed by Boehringer Ingelheim to ensure compliance
More informationInitial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care
Initial assessment of patient with AF in primary care DR BRUCE TAYLOR GPwSI Cardiology SCN Merseyside and Cheshire Clinical Lead Primary care 11 th and 25 th September 2014 3 KEY OBJECTIVES OF TALK 1.
More informationSignificance and Management Strategies for Patients with Asymptomatic Atrial Fibrillation
Significance and Management Strategies for Patients with Asymptomatic Atrial Fibrillation Ewa Majos, MD, Rafal Dabrowski MD, PhD, FESC Institute of Cardiology, Warsaw, Poland. Abstract Atrial fibrillation
More informationOutcomes and Safety of Antithrombotic Treatment in Patients Aged 80 Years or Older With Nonvalvular Atrial Fibrillation
Outcomes and Safety of Antithrombotic Treatment in Patients Aged 80 Years or Older With Nonvalvular Atrial Fibrillation Martín Ruiz Ortiz, MD, PhD*, Elías Romo, MD, Dolores Mesa, MD, PhD, Mónica Delgado,
More informationΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ
ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart
More information[ Original Research Cardiovascular Disease ] of atrial fibrillation (AF) and of antithrombotic treatment in patients with these conditions.
[ Original Research Cardiovascular Disease ] Stroke/Thromboembolism and Intracranial Hemorrhage in a Real-world Atrial Fibrillation Population The Complications of Atrial Fibrillation in the Bologna Area
More informationProfessor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham
New Guidelines for SPAF Professor DA Fitzmaurice Primary Care Clinical Sciences University of Birmingham Stroke prevention and atrial fibrillation Epidemiology of atrial fibrillation How common is it?
More informationAuthors Emma Tassie Graham Scotland Aileen R Neilson* *Corresponding Author
A model based cost-effectiveness analysis of opportunistic screening for identifying atrial fibrillation with a single lead handheld electrocardiogram monitor in general practices in Scotland Authors Emma
More informationReview Article. Payam Safavi-Naeini, MD, Mehdi Razavi, MD, Mohammad Saeed, MD, Abdi Rasekh, MD *, Ali Massumi, MD
TEHRAN HEART CENTER Review Article A Review of the LARIAT Suture Delivery Device for Left Atrial Appendage Closure Payam Safavi-Naeini, MD, Mehdi Razavi, MD, Mohammad Saeed, MD, Abdi Rasekh, MD *, Ali
More informationDOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017
DOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017 Disclosures for David Garcia Consultancy: Boehringer Ingelheim; Bristol-Meyers Squibb; Daiichi
More informationMake the Connection A clinical compendium on the relationship between AF, stroke, and early intervention
Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention Data that date back to the 1970 s have illustrated the strong relationship between atrial fibrillation
More informationComplicanze aritmiche in riabilitazione dopo CCH.
Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at
More informationTaggar, Jaspal (2017) Screening for atrial fibrillation in primary care. PhD thesis, University of Nottingham.
Taggar, Jaspal (2017) Screening for atrial fibrillation in primary care. PhD thesis, University of Nottingham. Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/44379/1/jaspal%20taggar%20phd%20write%20up
More informationAtrial Fibrillation. CVD Clinical Development Coordinator
Atrial Fibrillation CVD Clinical Development Coordinator Atrial Fibrillation What it is and why it's important Case identification Heart rate control and onward referral Managing AF-Related Stroke risk
More informationAtrial fibrillation (AF) is the most common arrhythmia
Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non-Valvular Atrial Fibrillation Moti Haim, MD; Moshe Hoshen, PhD;
More informationROLE OF IMAGING IN ARRHYTHMIA/DEVICES I ATRIAL FΙBRILLATION: CLINICAL TYPES AND OUTCOME (PROGNOSIS)
ROLE OF IMAGING IN ARRHYTHMIA/DEVICES I ATRIAL FΙBRILLATION: CLINICAL TYPES AND OUTCOME (PROGNOSIS) Κώστας Παπαδόπουλος, Επιμ. Α Καρδιολογίας, Νοσοκομείο Ερυθρός Σταυρός ATRIAL FIBRILATION - EPIDEMIOLOGY
More informationTreating Atrial Fibrillation. Richard Schilling. St Bartholomew's Hospital, Queen Mary s University of London
Treating Atrial Fibrillation Richard Schilling St Bartholomew's Hospital, Queen Mary s University of London AF burden Framingham Lifetime risk of developing AF = 25% Mortality: SMR =1.9 1.5 NHS audit 1%
More informationDevice detected AF and atrial high rate episodes
Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Hypertension QOF indicator area: Hypertension Date: July 2013
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationCosting statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS)
Putting NICE guidance into practice Costing statement: Atrial fibrillation and heart valve disease: selfmonitoring coagulation status using point-of-care coagulometers (the CoaguChek XS) Published: September
More informationAtrial fibrillation (AF) is the most common cardiac arrhythmia,
Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators The Multicentre Italian ANGELS of AF Project Giuseppe Boriani, MD, PhD; Massimo
More informationGRASP-AF- The National Picture. Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012
GRASP-AF- The National Picture Dr Richard Healicon National Improvement Lead Ian Robson Senior Analyst NHS Improvement February 2012 Outline AF and stroke Objective Management of stroke risk Stroke risk
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationORIGINAL ARTICLE. Tilt training and pacing: a report on 9 patients with neurally mediated syncope
Acta Cardiol 2010; 65(1): 3-7 doi: 10.2143/AC.65.1.2045882 3 ORIGINAL ARTICLE Tilt training and pacing: a report on 9 patients with neurally mediated syncope Tony REYBROUCK, PhD; Hein HEIDBÜCHEL, MD, PhD;
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationVon Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation
European Review for Medical and Pharmacological Sciences 2017; 21: 4907-4912 Von Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation
More information